The Australian Gaucher Disease Therapeutics market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Gaucher disease is a rare, inherited metabolic disorder in which deficiency of the enzyme glucocerebrosidase results in the accumulation of harmful quantities of certain fats (lipids), specifically the glycolipid glucocerebroside, throughout the body especially within the bone marrow, spleen and liver. The symptoms and physical findings associated with Gaucher disease vary greatly from patient to patient. Some individuals develop few or no symptoms (asymptomatic); others may have serious complications.
All forms of Gaucher disease affect males and females in equal numbers. Gaucher disease type 1 is the most common type. The age of onset for Gaucher disease type 2 is during early infancy. The age of onset of Gaucher disease type 3 varies, but the disorder generally begins during childhood or adolescence. There is no ethnic prevalence associated with Gaucher disease types 2 or 3.
The key market drivers for Gaucher Disease Therapeutics market are increasing prevalence of rare genetic disorders, increase in number of drug approvals for management of disease. Additionally, high investments by drug companies to develop novel therapies for treatment of such diseases is likely to fuel market growth during forecast period, whereas lack of awareness about such kind of rare genetic disorders among people is expected to restrain market growth during forecast period.
Major Gaucher Disease Clinical Types
The Australian Gaucher Disease market has been segmented on the basis of clinical type into type I, type II and type III. The type I occupied the largest market of Gaucher disease across the Australian Market.